PDCD1 and head and neck squamous cell carcinoma: After the development of PD-1 ICIs to treat R/M HNSCC, the clinicopathological and prognostic significance of PD-1 and PD-L1 expression were studied, but most studies used a cut-off value or a percentage for evaluation [13, 14].